A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic cancer

Jong Gwon Choi, Jae Hong Seo, Sang Cheul Oh, Chul Won Choi, Jun Suk Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. Materials and Methods: Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle. Results: Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95% CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI, 2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%), and hand-foot syndrome (10%). Conclusion: Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalCancer Research and Treatment
Volume44
Issue number2
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

gemcitabine
Pancreatic Neoplasms
Hand-Foot Syndrome
Drug Therapy
Combination Drug Therapy
Neutropenia
Thrombocytopenia
Capecitabine
Anemia
Adenocarcinoma
Radiotherapy
Safety

Keywords

  • Capecitabine
  • Gemcitabine
  • Pancreatic neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic cancer. / Choi, Jong Gwon; Seo, Jae Hong; Oh, Sang Cheul; Choi, Chul Won; Kim, Jun Suk.

In: Cancer Research and Treatment, Vol. 44, No. 2, 01.06.2012, p. 127-132.

Research output: Contribution to journalArticle

@article{a530cf93ac4c4377b4e24157663f1e19,
title = "A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic cancer",
abstract = "Purpose: The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. Materials and Methods: Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle. Results: Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0{\%} (95{\%} CI, 22.5 to 57.1{\%}). The median time to progression and overall survival were 6.5 months (95{\%} CI, 2.3 to 8.7 months) and 10.0 months (95{\%} CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22{\%}), anemia (8{\%}), thrombocytopenia (6{\%}), and hand-foot syndrome (10{\%}). Conclusion: Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.",
keywords = "Capecitabine, Gemcitabine, Pancreatic neoplasms",
author = "Choi, {Jong Gwon} and Seo, {Jae Hong} and Oh, {Sang Cheul} and Choi, {Chul Won} and Kim, {Jun Suk}",
year = "2012",
month = "6",
day = "1",
doi = "10.4143/crt.2012.44.2.127",
language = "English",
volume = "44",
pages = "127--132",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "2",

}

TY - JOUR

T1 - A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic cancer

AU - Choi, Jong Gwon

AU - Seo, Jae Hong

AU - Oh, Sang Cheul

AU - Choi, Chul Won

AU - Kim, Jun Suk

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Purpose: The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. Materials and Methods: Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle. Results: Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95% CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI, 2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%), and hand-foot syndrome (10%). Conclusion: Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.

AB - Purpose: The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. Materials and Methods: Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle. Results: Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95% CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI, 2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%), and hand-foot syndrome (10%). Conclusion: Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.

KW - Capecitabine

KW - Gemcitabine

KW - Pancreatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84866922880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866922880&partnerID=8YFLogxK

U2 - 10.4143/crt.2012.44.2.127

DO - 10.4143/crt.2012.44.2.127

M3 - Article

C2 - 22802751

AN - SCOPUS:84866922880

VL - 44

SP - 127

EP - 132

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -